Bupropion

Martin Huecker; Abbey Smiley; Abdolreza Saadabadi

Bupropion

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Bupropion is an antidepressant medication that has received FDA approval for the treatment of depression and seasonal affective disorder and as an aid for smoking cessation. Since its approval in 1985, bupropion has been utilized off-label for various conditions, including antidepressant-induced sexual dysfunction, depression associated with bipolar disorder, obesity, and ADHD in pediatric patients. This activity reviews bupropion's clinical applications, including indications, dosing, mechanism of action, adverse event profile, and toxicity. By understanding bupropion's pharmacological properties, healthcare professionals can optimize treatment regimens and reduce the risk of adverse effects, thereby improving patient outcomes. The activity also emphasizes the essential role of the interprofessional healthcare team in managing bupropion therapy, underlining the significance of collaboration and well-defined roles in patient care.

Objectives:

Identify the FDA-approved and off-label indications of bupropion.
Assess the mechanism of action of bupropion.
Screen patients for contraindications and potential risks associated with bupropion therapy.
Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from bupropion therapy.

Indications

Bupropion is an antidepressant that can also help patients stop smoking. This medication was first patented by Burroughs Wellcome (now part of GlaxoSmithKline) in 1974 and approved by the FDA in 1985. Under the brand name, Wellbutrin, the sustained-release (SR) formula was introduced in 1996, and the extended-release (XL) formulation was introduced in 2003.[1][2] In 1997, bupropion was introduced for the smoking cessation indication.[3] Until the year 2000, the drug was sometimes referred to as amfebutamone.

FDA-Approved Indications

Adult depression
Seasonal affective disorder
Smoking cessation [4][5][6][7]

Off-Label Uses

Antidepressant-induced sexual dysfunction
Attention-deficit/hyperactivity disorder (ADHD)
Depression associated with bipolar disorder
Obesity [8][9]
ADHD in pediatric patients [10]

The American Gastroenterological Association (AGA) advises incorporating naltrexone-bupropion extended-release (ER) alongside lifestyle changes for adults with obesity instead of relying solely on lifestyle changes.[11]

The American Thoracic Society (ATS) guidelines suggest that bupropion can be used for tobacco dependence; however, varenicline is preferred over bupropion. The ATS acknowledges that future studies should assess the relative clinical effects of varenicline and bupropion in specific at-risk groups, including pregnant women, adolescents, and patients with a history of treatment resistance.[12]

The American Society of Addiction Medicine and the American Academy of Addiction Psychiatry Clinical Practice Guidelines for stimulant use disorder suggest that for patients with cocaine use disorder, clinicians may consider prescribing bupropion to support cocaine abstinence. Bupropion may also be considered for patients with co-occurring tobacco use disorder, as it can help reduce nicotine or tobacco use, and for those with co-occurring depression. For patients with amphetamine-type stimulant use disorder who use stimulants with low to moderate frequency (fewer than 18 days per month), clinicians may consider prescribing bupropion to reduce stimulant use. Additionally, bupropion may be considered for patients with co-occurring tobacco use disorder or depressive disorders for the same reasons mentioned above.[13]

Mechanism of Action

Depression

Bupropion is an aminoketone antidepressant, and its mechanism of action is not fully understood.[14] Bupropion inhibits dopamine and norepinephrine transporters (DAT and NET), reducing the reuptake of these neurotransmitters. The drug reduces noradrenergic neuron activity in the locus coeruleus and increases dopaminergic activity in the nucleus accumbens. Bupropion has minimal effects on serotonin activity. The exact therapeutic mechanism in major depressive disorder is not fully defined but involves the selective inhibition of norepinephrine and dopamine reuptake.[15][16][17]

Smoking Cessation

Nicotine activates cholinergic receptors in the brain and body, releasing neurotransmitters such as acetylcholine, dopamine, norepinephrine, and serotonin. The addictive properties of nicotine are primarily the result of dopamine release in reward-related brain areas such as the ventral tegmental area and nucleus accumbens. Bupropion supports smoking cessation by targeting these circuits, providing anti-craving and anti-withdrawal benefits. The drug inhibits the reuptake of dopamine and norepinephrine, disrupting the reward pathways linked to nicotine addiction. Additionally, bupropion may act on nicotinic cholinergic receptors, improving its effectiveness in smoking cessation.[17]

Pharmacokinetics

Absorption: Bupropion is rapidly absorbed from the gastrointestinal tract. Peak serum concentrations are achieved at 2 hours for immediate release, 3 hours for sustained-release, and 5 hours for extended-release. The duration of action is 1 to 2 days. The onset of bupropion's therapeutic effect usually occurs during the second week of therapy.

Distribution: The volume of distribution of bupropion ranges from 20 L/kg to 47 L/kg. The plasma protein binding is approximately 85%.[18]

Metabolism: Bupropion is metabolized to hydroxybupropion by hepatic CYP2B6.[19] Non-CYP metabolism follows to form erythro-hydrobupropion and threo-hydrobupropion. These metabolites demonstrate a potency of 20% to 50% of the parent compound. Glycinated conjugate forms of these metabolites are eliminated renally.

Elimination: Approximately 10% of the drug is excreted in the feces and 87% in the urine.[20] The distribution half-life is 3 to 4 hours. The elimination half-life of bupropion is approximately 21 hours.[18]

Administration

Available Dosage Forms and Strengths

Bupropion is administered orally; tablets are available in regular or extended-release formulations. Patients may take the medication with or without meals. The tablets should be swallowed whole without crushing or dividing.

The once-daily dosage form ranges from 75 mg to 522 mg, depending on the formulation.

Immediate-release:

Available in 75 mg and 100 mg

Extended-release:

12-hour tablets (hydrochloride) are available in 100 mg, 150 mg, and 200 mg
24-hour tablets (hydrobromide) are available in 174 mg, 348 mg, and 522 mg
24-hour tablets (hydrochloride) are available in 150 mg, 300 mg, and 450 mg

Adult Dosage

Smoking Cessation

The initial dose for smoking cessation is 150 mg once daily for 3 days. This is increased to 150 mg twice daily for 7 to 12 weeks. The quit attempt is typically initiated after a week of therapy.[21] The maximum daily dose is 450 mg.[22]

Seasonal Affective Disorder

The initial dose is 150 mg (XL) once daily. After 7 days, the dose may be increased to 300 mg once daily in the morning. Treatment typically begins in autumn before depressive symptoms appear and continues through winter. Dosing is tapered to 150 mg, then discontinued in early spring. Treatment timing and duration may be adjusted based on the patient's seasonal MDD pattern. Bupropion hydrobromide can be given orally at 174 mg daily, and after 1 week, the dosage can be increased to a maintenance dose of 348 mg.

Major Depressive Disorder

Immediate-release: Treatment is initiated at 100 mg every 12 hours. This is increased to 100 mg every 8 hours on day 4. If therapeutic goals are not met on 100mg every 8 hours after several weeks, the maximum dose of 150 mg can be taken every 8 hours.

Sustained-release: Treatment is initiated at 150 mg once daily. Clinicians can consider increasing the dose to 150 mg every 12 hours starting day 4. If therapeutic goals are unmet after 4 weeks on 150 mg every 12 hours, the maximum dosage is 200 mg every 12 hours.

Extended-release: Treatment is initiated at 150 mg once daily. Clinicians may increase the dose to 300 mg once daily on day 4. If no clinical improvement is observed after 4 weeks, the dosage may be increased to 450 mg daily.

Maintenance treatment with all formulations typically requires several months or longer beyond the initial response; patients should be assessed periodically to determine the need and dose for maintenance.

Dosage switching considerations

Forfivo XL can be used only after titrating initially with other bupropion medications.

Patients with MDD switching from XL should be given the same daily dose divided equally: 3 times daily for IR, twice daily for SR, and once daily for the XL formulation.

When switching from hydrochloride salt formulation to hydrobromide salt (Aplenzin):

150 mg/day hydrochloride salt = 174 mg/day hydrobromide salt
300 mg/day hydrochloride salt = 348 mg/day hydrobromide salt
450 mg/day hydrochloride salt = 522 mg/day hydrobromide salt

Specific Patient Populations

Hepatic impairment: According to the American Association for the Study of Liver Diseases (AASLD), antidepressants should be started at low doses in individuals with chronic liver disease (CLD). For patients receiving bupropion, the dose should be reduced by 50%, with subsequent adjustments based on the balance between therapeutic response and adverse effects.[23]

Renal impairment: For patients with renal impairment, the elimination of bupropion metabolites is reduced. Therefore, bupropion should be used cautiously, and dose adjustments are required. The maximum recommended dose for patients with an eGFR of 30 to 60 mL/min is 150 mg daily.[24]

Pregnancy considerations: Bupropion is a pregnancy class C drug. Treating pregnant women with depression requires balancing the risks of fetal medication exposure with the potential harms of untreated depression. Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are first-line treatments for these patients. Selective serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, and sertraline are preferred medications due to their proven efficacy and safety. Bupropion is generally avoided due to limited safety data.[25]

Breastfeeding considerations: Bupropion and its metabolites are secreted into breast milk.[26][27] Maternal doses of up to 300 mg daily result in minimal bupropion levels in breast milk and are unlikely to cause adverse effects in breastfed infants. However, due to limited data and case reports suggesting potential risks, such as seizures in partially breastfed infants, bupropion should be used with caution. Alternative medications may be preferred, especially for patients with breastfeeding newborns or preterm infants, and close monitoring for symptoms such as vomiting or sedation is recommended.[28]

Pediatric patients: Bupropion is used off-label for children with attention deficit hyperactivity disorder. The usual starting dose is 3 mg/kg daily, which can be titrated to a maximum of 6 mg/kg daily.[29][30][31] The maximum recommended dose for these patients is 150 mg. Children receiving bupropion should be monitored closely.

Older patients: Bupropion is metabolized in the liver and excreted by the kidneys, so dose adjustments and renal function monitoring are advised, especially for older adults with impaired renal function.

Adverse Effects

Various adverse effects have been reported in patients receiving bupropion. Many of these side effects occur in more than 10% of patients.[32][33][34][35]

Cardiovascular

Hypertension
Tachycardia [36]

Respiratory

Rhinitis
Pharyngitis [37]

Central nervous system

Insomnia
Headache
Agitation
Dizziness [38][39]

Dermatologic

Pruritus
Diaphoresis [40]

Endocrine

Weight loss [41]

Gastrointestinal

Constipation
Dry mouth
Nausea [42]

Musculoskeletal

Tremor [43]
Arthritis [44]

Ophthalmologic

Blurred vision [43]

The most severe adverse effects include a lowered seizure threshold and worsening suicidal ideation.[39]

Clinicians and researchers first noted epileptic seizures occurring in the 1980s; bupropion was subsequently removed from the market from 1986 through 1989. The immediate-release preparation, especially in higher doses, appears to have the highest likelihood of causing seizures.[45] Bupropion is one of the very few antidepressants that does not cause sexual dysfunction.[46]

Drug-Drug Interactions

CYP2B6 inducers: Bupropion is metabolized by CYP2B6, so dose adjustments may be needed with inducers like ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin.[47]

CYP2D6 substrates: Bupropion inhibits CYP2D6 (dose-dependent), potentially increasing levels of drugs such as venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline, haloperidol, risperidone, thioridazine, metoprolol, propafenone, and flecainide. A dose reduction of these drugs may be required.[48]

Digoxin: Bupropion may reduce plasma levels of digoxin; these levels should be monitored closely.[47]

Drugs reducing seizure threshold: Use bupropion cautiously with medications that lower the seizure threshold, including antipsychotics, antidepressants, theophylline, and systemic corticosteroids. Bupropion should be initiated at low doses and increased gradually.

Dopaminergic Drugs: Coadministration with dopaminergic drugs like levodopa and amantadine may lead to CNS toxicity.[49] Patients receiving these drugs should be monitored for symptoms such as restlessness, agitation, tremors, ataxia, gait disturbance, vertigo, and dizziness.

Monoamine Oxidase Inhibitors (MAOIs): Using bupropion with MAOIs can increase the risk of hypertensive reactions.[50]

Contraindications

Patients who are hypersensitive or allergic to bupropion or its constituents should not use the medication.

Bupropion is contraindicated for patients with seizure disorder. Additionally, bupropion is also contraindicated for any other factors predisposing to seizures, ie, discontinuation of alcohol or sedatives, arteriovenous malformations, severe head injury, severe stroke, brain tumor, or other significant central nervous system disease.[51]

Patients taking monoamine oxidase inhibitors, linezolid, or methylene blue should not take bupropion. Additionally, Canadian regulations prohibit the concomitant use of thioridazine.[52][53]

Patients with a history of bulimia or anorexia nervosa should not take bupropion.

Box Warnings

Bupropion has an FDA-issued box warning related to suicidal thoughts and behavior in children, adolescents, and young adults. All patients who have depressive symptoms and begin any new medication should be monitored closely for suicidal signs. If symptoms worsen or overt suicidality ensues, the clinician should stop therapy.[54] In December 2016, researchers released a safety review; data from a large clinical trial convinced the FDA that the severe mood and behavior effects of bupropion are lower than previously represented. As a result, the FDA warning for bupropion for smoking cessation changed. However, the report notes that these reactions remain concerning, especially in patients with severe mood disorders or schizophrenia. This FDA report was explicitly related to the use of bupropion in smoking cessation.

Warnings and Precautions

False positive amphetamine urine drug screens have been reported with the administration of bupropion; urine assays should be interpreted with caution before diagnosing substance use.[55]
The doses and preparations of bupropion prescribed for the treatment of depression should be prescribed cautiously.[56]

Monitoring

Bupropion does not require monitoring with serum testing, and there are no firmly established therapeutic concentrations of the drug. Patients should be monitored clinically for serious adverse effects. Some patients tolerate bupropion better at lower serum concentrations; therefore, clinicians should attempt lower initial doses in all patients.

Due to its metabolism by CYP enzymes, bupropion interacts with various medications. Before prescribing, the provider should determine if any existing medications interact with bupropion. Medicines known to interact with bupropion include antidepressants, clopidogrel, and other drugs that lower the seizure threshold. Patients need to limit alcohol intake while on bupropion.[18]

Toxicity

Signs and Symptoms of Overdose

There is extensive published data regarding bupropion overdose.[57] The more severe exposures typically occur in an intentional overdose setting. With supportive care, unintentional overdoses usually lead to no significant effects. Accidental exposures in children are rare; a proposed 10 mg/kg safety threshold is proposed to reduce the use of healthcare resources.[58]

Seizures occur in 10% to 15% of intentional overdoses and typically occur within the first 6 hours after exposure. In overdoses of extended-release formulations, experts recommend an observation period of 24 hours due to the potential for delayed seizure onset. Though agitation and tremor often precede seizures, delayed seizures with no prior symptoms have been observed.[59] Other effects include hallucinations, mental status changes, agitation, and arrhythmias.[60][36] The treating clinician should rule out the presence of coingestants. Bupropion misuse is rare but has been reported.[61]

Management of Overdose

Seizures should be treated with intravenous benzodiazepines. Bupropion and hydroxybupropion are highly lipid-soluble, and intravenous lipid emulsion therapy can help treat bupropion overdose.[62] Successful use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been documented in patients with severe cardiotoxicity associated with bupropion overdose.[63]

Enhancing Healthcare Team Outcomes

Physicians and nurse practitioners frequently prescribe bupropion. However, all healthcare workers who prescribe this agent must be familiar with its associated adverse effects, which occur in at least 10% of patients. The most severe adverse effects include a lowered seizure threshold and the potential worsening of suicidal ideation. Clinicians should perform a mental health assessment of patients at each visit and educate them on what to do if and when a seizure develops.[64] Pharmacists and nurses should also participate in these monitoring activities, perform medication reconciliation before drug administration, and inform the rest of the team of any concerns. This type of collaboration and communication can lead to more successful outcomes with bupropion therapy. An interprofessional team approach and communication among clinicians, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes related to bupropion therapy.

Details

References

[1]

Settle EC Jr. Bupropion sustained release: side effect profile. The Journal of clinical psychiatry. 1998:59 Suppl 4():32-6 [PubMed PMID: 9554319]

[2]

Jefferson JW. Bupropion extended-release for depressive disorders. Expert review of neurotherapeutics. 2008 May:8(5):715-22. doi: 10.1586/14737175.8.5.715. Epub [PubMed PMID: 18457528]

[3]

Wilkes S. Bupropion. Drugs of today (Barcelona, Spain : 1998). 2006 Oct:42(10):671-81 [PubMed PMID: 17136226]

[4]

Hsieh MT, Tseng PT, Wu YC, Tu YK, Wu HC, Hsu CW, Lei WT, Stubbs B, Carvalho AF, Liang CS, Yeh TC, Chen TY, Chu CS, Li JC, Yu CL, Chen YW, Li DJ. Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2019 Jun:20(6):895-905. doi: 10.1111/obr.12835. Epub 2019 Feb 27 [PubMed PMID: 30816006]

Level 1 (high-level) evidence

[5]

Hankosky ER, Bush HM, Dwoskin LP, Harris DR, Henderson DW, Zhang GQ, Freeman PR, Talbert JC. Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission. AMIA ... Annual Symposium proceedings. AMIA Symposium. 2018:2018():1292-1299 [PubMed PMID: 30815171]

Level 2 (mid-level) evidence

[6]

Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Hajek P. Relapse prevention interventions for smoking cessation. The Cochrane database of systematic reviews. 2019 Feb 13:2(2):CD003999. doi: 10.1002/14651858.CD003999.pub5. Epub 2019 Feb 13 [PubMed PMID: 30758045]

Level 1 (high-level) evidence

[7]

Patel AR, Panchal JR, Desai CK. Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials. Indian journal of psychiatry. 2023 May:65(5):526-533. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_218_22. Epub 2023 May 15 [PubMed PMID: 37397838]

Level 1 (high-level) evidence

[8]

Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sexual medicine. 2018 Jun:6(2):59-74. doi: 10.1016/j.esxm.2018.01.004. Epub 2018 Mar 6 [PubMed PMID: 29523488]

[9]

Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. The Cochrane database of systematic reviews. 2017 Oct 2:10(10):CD009504. doi: 10.1002/14651858.CD009504.pub2. Epub 2017 Oct 2 [PubMed PMID: 28965364]

Level 1 (high-level) evidence

[10]

Ng QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Journal of child and adolescent psychopharmacology. 2017 Mar:27(2):112-116. doi: 10.1089/cap.2016.0124. Epub 2016 Nov 4 [PubMed PMID: 27813651]

Level 1 (high-level) evidence

[11]

Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P, AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 Nov:163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20 [PubMed PMID: 36273831]

Level 1 (high-level) evidence

[12]

Leone FT, Zhang Y, Evers-Casey S, Evins AE, Eakin MN, Fathi J, Fennig K, Folan P, Galiatsatos P, Gogineni H, Kantrow S, Kathuria H, Lamphere T, Neptune E, Pacheco MC, Pakhale S, Prezant D, Sachs DPL, Toll B, Upson D, Xiao D, Cruz-Lopes L, Fulone I, Murray RL, O'Brien KK, Pavalagantharajah S, Ross S, Zhang Y, Zhu M, Farber HJ. Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2020 Jul 15:202(2):e5-e31. doi: 10.1164/rccm.202005-1982ST. Epub [PubMed PMID: 32663106]

Level 1 (high-level) evidence

[13]

Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, IRETA Team. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Journal of addiction medicine. 2024 May-Jun 01:18(1S Suppl 1):1-56. doi: 10.1097/ADM.0000000000001299. Epub [PubMed PMID: 38669101]

Level 1 (high-level) evidence

[14]

Paccosi S, Cresci B, Pala L, Rotella CM, Parenti A. Obesity Therapy: How and Why? Current medicinal chemistry. 2020:27(2):174-186. doi: 10.2174/0929867326666190124121725. Epub [PubMed PMID: 30678612]

[15]

Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Primary care companion to the Journal of clinical psychiatry. 2004:6(4):159-166 [PubMed PMID: 15361919]

[16]

Shalabi AR, Walther D, Baumann MH, Glennon RA. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. ACS chemical neuroscience. 2017 Jun 21:8(6):1397-1403. doi: 10.1021/acschemneuro.7b00055. Epub 2017 Feb 27 [PubMed PMID: 28220701]

[17]

Clark A, Tate B, Urban B, Schroeder R, Gennuso S, Ahmadzadeh S, McGregor D, Girma B, Shekoohi S, Kaye AD. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation. Health psychology research. 2023:11():81043. doi: 10.52965/001c.81043. Epub 2023 Jul 1 [PubMed PMID: 37405312]

[18]

Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clinical therapeutics. 2005 Nov:27(11):1685-95 [PubMed PMID: 16368442]

[19]

Eum S, Sayre F, Lee AM, Stingl JC, Bishop JR. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis. Pharmacotherapy. 2022 Jan:42(1):34-44. doi: 10.1002/phar.2644. Epub 2021 Nov 23 [PubMed PMID: 34752647]

Level 1 (high-level) evidence

[20]

Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of bupropion by carbonyl reductases in liver and intestine. Drug metabolism and disposition: the biological fate of chemicals. 2015 Jul:43(7):1019-27. doi: 10.1124/dmd.115.063107. Epub 2015 Apr 22 [PubMed PMID: 25904761]

[21]

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. The Cochrane database of systematic reviews. 2014 Jan 8:2014(1):CD000031. doi: 10.1002/14651858.CD000031.pub4. Epub 2014 Jan 8 [PubMed PMID: 24402784]

Level 1 (high-level) evidence

[22]

Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002:62 Suppl 2():45-52 [PubMed PMID: 12109935]

[23]

Cotter TG, Beresford T. Treatment of Mental Health in Patients With Chronic Liver Disease. Clinical liver disease. 2022 Aug:20(2):57-60. doi: 10.1002/cld.1200. Epub 2022 May 23 [PubMed PMID: 36033423]

[24]

Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Oct:27(10):3736-45. doi: 10.1093/ndt/gfs295. Epub 2012 Aug 1 [PubMed PMID: 22859791]

Level 1 (high-level) evidence

[25]

MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, Ravindran AV, CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2016 Sep:61(9):588-603. doi: 10.1177/0706743716659276. Epub 2016 Aug 2 [PubMed PMID: 27486149]

[26]

Davis JS, Boyle MJ, Hannaford R, Watson A. Bupropion and serum sickness-like reaction. The Medical journal of Australia. 2001 May 7:174(9):479-80 [PubMed PMID: 11386597]

[27]

Fokina VM, Xu M, Rytting E, Abdel-Rahman SZ, West H, Oncken C, Clark SM, Ahmed MS, Hankins GD, Nanovskaya TN. Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. Drug metabolism and disposition: the biological fate of chemicals. 2016 Nov:44(11):1832-1838 [PubMed PMID: 27528039]

[28]

. Bupropion. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000243]

[29]

Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. Journal of central nervous system disease. 2013:5():1-17. doi: 10.4137/JCNSD.S6691. Epub 2012 Dec 20 [PubMed PMID: 23650474]

[30]

Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2007 Jul:46(7):894-921 [PubMed PMID: 17581453]

Level 2 (mid-level) evidence

[31]

Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J. Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry. 1996 Oct:35(10):1314-21 [PubMed PMID: 8885585]

[32]

Cohen JB, Gadde KM. Weight Loss Medications in the Treatment of Obesity and Hypertension. Current hypertension reports. 2019 Feb 12:21(2):16. doi: 10.1007/s11906-019-0915-1. Epub 2019 Feb 12 [PubMed PMID: 30747357]

[33]

Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International journal of obesity (2005). 2019 Oct:43(10):2085-2094. doi: 10.1038/s41366-018-0302-z. Epub 2019 Jan 21 [PubMed PMID: 30664661]

[34]

Correia MS, Whitehead E, Cantrell FL, Lasoff DR, Minns AB. A 10-year review of single medication double-dose ingestions in the nation's largest poison control system. Clinical toxicology (Philadelphia, Pa.). 2019 Jan:57(1):31-35. doi: 10.1080/15563650.2018.1493205. Epub 2018 Nov 28 [PubMed PMID: 30484705]

[35]

Dagan Y, Yager J. Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD. The International journal of eating disorders. 2018 Oct:51(10):1207-1209. doi: 10.1002/eat.22948. Epub 2018 Sep 19 [PubMed PMID: 30230570]

[36]

Druteika D, Zed PJ. Cardiotoxicity following bupropion overdose. The Annals of pharmacotherapy. 2002 Nov:36(11):1791-5 [PubMed PMID: 12398578]

[37]

Tackett AE, Smith KM. Bupropion-induced angioedema. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2008 Sep 1:65(17):1627-30. doi: 10.2146/ajhp070575. Epub [PubMed PMID: 18714109]

[38]

Richards JR, Gould JB, Laurin EG, Albertson TE. Metoprolol treatment of dual cocaine and bupropion cardiovascular and central nervous system toxicity. Clinical and experimental emergency medicine. 2019 Mar:6(1):84-88. doi: 10.15441/ceem.17.247. Epub 2018 Jan 31 [PubMed PMID: 29381909]

[39]

Ross S, Williams D. Bupropion: risks and benefits. Expert opinion on drug safety. 2005 Nov:4(6):995-1003 [PubMed PMID: 16255659]

Level 3 (low-level) evidence

[40]

Lineberry TW, Peters GE Jr, Bostwick JM. Bupropion-induced erythema multiforme. Mayo Clinic proceedings. 2001 Jun:76(6):664-6 [PubMed PMID: 11393509]

[41]

Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity facts. 2011:4(6):489-94. doi: 10.1159/000335352. Epub 2011 Dec 15 [PubMed PMID: 22249001]

[42]

Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. International journal of geriatric psychiatry. 2001 Sep:16(9):862-5 [PubMed PMID: 11571765]

[43]

Knowles SR, Shapiro LE, Shear NH. Reactive metabolites and adverse drug reactions: clinical considerations. Clinical reviews in allergy & immunology. 2003 Jun:24(3):229-38 [PubMed PMID: 12721394]

[44]

Yuan W, Williams BN. Monoarthritis Induced by Bupropion Hydrochloride. Psychopharmacology bulletin. 2011 May 15:44(2):85-87 [PubMed PMID: 27738357]

[45]

Tripp AC. Bupropion, a brief history of seizure risk. General hospital psychiatry. 2010 Mar-Apr:32(2):216-7. doi: 10.1016/j.genhosppsych.2009.11.004. Epub 2009 Dec 14 [PubMed PMID: 20302998]

[46]

Rothmore J. Antidepressant-induced sexual dysfunction. The Medical journal of Australia. 2020 Apr:212(7):329-334. doi: 10.5694/mja2.50522. Epub 2020 Mar 15 [PubMed PMID: 32172535]

[47]

Gaya PV, Santos JR, Tomaz PRX, Abe TMO, Nassif M Jr, Galas LG, Bellini BB, Moraes IR, Santos PCL, Correa PCRP, Scholz JR. Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial - GENTSMOKING. Tobacco induced diseases. 2024:22():. doi: 10.18332/tid/186072. Epub 2024 Apr 16 [PubMed PMID: 38628555]

Level 1 (high-level) evidence

[48]

Hole K, Arnestad M, Molden E, Haslemo T. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Journal of clinical psychopharmacology. 2021 May-Jun 01:41(3):281-285. doi: 10.1097/JCP.0000000000001387. Epub [PubMed PMID: 33905640]

[49]

Vismara M, Benatti B, Nicolini G, Cova I, Monfrini E, Di Fonzo A, Fetoni V, Viganò CA, Priori A, Dell'Osso B. Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC neurology. 2022 May 5:22(1):169. doi: 10.1186/s12883-022-02668-4. Epub 2022 May 5 [PubMed PMID: 35513785]

Level 2 (mid-level) evidence

[50]

Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 1997 Mar:9(1):7-13 [PubMed PMID: 9167831]

Level 2 (mid-level) evidence

[51]

Richmond R, Zwar N. Review of bupropion for smoking cessation. Drug and alcohol review. 2003 Jun:22(2):203-20 [PubMed PMID: 12850907]

[52]

West R. Bupropion SR for smoking cessation. Expert opinion on pharmacotherapy. 2003 Apr:4(4):533-40 [PubMed PMID: 12667116]

Level 3 (low-level) evidence

[53]

Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2016 May:149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8 [PubMed PMID: 27212965]

[54]

Shah D, Shah A, Tan X, Sambamoorthi U. Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States. Drug and alcohol dependence. 2017 Aug 1:177():187-193. doi: 10.1016/j.drugalcdep.2017.03.021. Epub 2017 May 18 [PubMed PMID: 28605678]

[55]

Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2011 Jun:7(2):105-8. doi: 10.1007/s13181-010-0131-5. Epub [PubMed PMID: 21191682]

Level 3 (low-level) evidence

[56]

Saiz Ruiz J, Gibert J, Gutiérrez Fraile M, Bobes J, Vallejo J, Iglesias C, Iriarte V. Bupropion: efficacy and safety in the treatment of depression. Actas espanolas de psiquiatria. 2011:39 Suppl 1():1-25 [PubMed PMID: 22983817]

[57]

Overberg A, Morton S, Wagner E, Froberg B. Toxicity of Bupropion Overdose Compared With Selective Serotonin Reuptake Inhibitors. Pediatrics. 2019 Aug:144(2):. pii: e20183295. doi: 10.1542/peds.2018-3295. Epub 2019 Jul 5 [PubMed PMID: 31278211]

[58]

Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. The Journal of emergency medicine. 2004 Aug:27(2):147-51 [PubMed PMID: 15261357]

[59]

Offerman S, Gosen J, Thomas SH, Padilla-Jones A, Ruha AM, Levine M. Bupropion associated seizures following acute overdose: who develops late seizures. Clinical toxicology (Philadelphia, Pa.). 2020 Dec:58(12):1306-1312. doi: 10.1080/15563650.2020.1742919. Epub 2020 Mar 26 [PubMed PMID: 32212940]

[60]

Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. The Medical journal of Australia. 2003 Jan 20:178(2):61-3 [PubMed PMID: 12526723]

Level 2 (mid-level) evidence

[61]

Stassinos GL, Klein-Schwartz W. Bupropion "Abuse" Reported to US Poison Centers. Journal of addiction medicine. 2016 Sep-Oct:10(5):357-62. doi: 10.1097/ADM.0000000000000249. Epub [PubMed PMID: 27504927]

[62]

Bornstein K, Montrief T, Anwar Parris M. Successful Management of Adolescent Bupropion Overdose with Intravenous Lipid Emulsion Therapy. Journal of pediatric intensive care. 2019 Dec:8(4):242-246. doi: 10.1055/s-0039-1693483. Epub 2019 Jul 25 [PubMed PMID: 31673461]

[63]

Pires KD, Bloom J, Golob S, Sahagún BE, Greco AA, Chebolu E, Yang J, Ting P, Postelnicu R, Soetanto V, Joseph L, Bangalore S, Hall SF, Biary R, Hoffman RS, Park DS, Alviar CL, Harari R, Smith SW, Su MK. Successful Treatment of Confirmed Severe Bupropion Cardiotoxicity With Veno-Arterial Extracorporeal Membrane Oxygenation Initiation Prior to Cardiac Arrest. Cureus. 2024 Feb:16(2):e53768. doi: 10.7759/cureus.53768. Epub 2024 Feb 7 [PubMed PMID: 38465186]

[64]

Yang YC, Yeh TC, Liang CS. A case of recurrent seizures: Drug-drug interaction between low-dose clozapine and extended-release bupropion. The Australian and New Zealand journal of psychiatry. 2019 Feb:53(2):175-176. doi: 10.1177/0004867418812681. Epub 2018 Nov 18 [PubMed PMID: 30449126]

Level 3 (low-level) evidence